SOPHiA GENETICS has announced a significant expansion of its partnership with AstraZeneca, entering into a new, multi-year collaboration to advance breast cancer care using artificial intelligence. This partnership will utilize SOPHiA GENETICS' AI Factories to analyze a wide range of patient data, including genomics, medical imaging, and clinical records. By generating AI-powered insights, the companies aim to produce real-world evidence on the efficacy and value of breast cancer therapies, ultimately helping to optimize treatment for individual patients.

A key focus of the collaboration is the development of a bespoke AI-powered predictive model specifically designed to improve outcomes for breast cancer patients. This model will be trained on diverse multimodal datasets, allowing for a more holistic understanding of disease biology and biomarkers. Both companies will work together on real-world evidence generation in Europe and North America to identify the main drivers of treatment efficacy, close existing knowledge gaps, and provide clinicians with deeper insights for making better decisions. The initiative highlights a shared commitment to using secure, scalable AI and federated data analytics to drive better patient outcomes and reinforces SOPHiA GENETICS' role as a trusted technology partner in the healthcare industry.